MedTrace Logo

LYT-100 in Post-acute COVID-19 Respiratory Disease

NCT04652518 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 185

Last updated 2024-02-14

No results posted yet for this study

Summary

This study is being conducted in two parts, A and B. Part A is a randomized, double-blind, parallel arm study to evaluate the safety and efficacy of LYT-100 compared to placebo in adults with post-acute COVID-19 respiratory complications. Part B is an Open Label Extension (OLE) study for patients who complete Part A.

Conditions

  • Covid19
  • Post-acute COVID-19 Respiratory Disease

Interventions

DRUG

LYT-100

oral administration

OTHER

Placebo

oral administration

Sponsors & Collaborators

  • Clinipace Worldwide

    collaborator INDUSTRY

  • Novotech (Australia) Pty Limited

    collaborator INDUSTRY

  • PureTech

    lead INDUSTRY

Principal Investigators

  • Toby Maher, MD · Keck School of Medicine, University of Southern California

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-11
Primary Completion
2022-06-28
Completion
2022-07-18
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Brazil
  • Moldova
  • Philippines
  • Romania
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04652518 on ClinicalTrials.gov